1952年，好萊塢米高梅片廠的排練室裡，年僅19歲的美國女演員黛比．雷諾斯（Debbie Reynolds）崩潰了。當時她正在為經典歌舞片《萬花嬉春》（Singing in the Rain）做準備，這是她首度擔綱女主角，與傳奇舞者金．凱利（Gene Kelly）搭檔演出。她請了三位舞蹈老師，每天連續旋轉練習八個小時。
In 1952, inside a rehearsal room at MGM Studios in Hollywood, 19-year-old American actress Debbie Reynolds had a breakdown. She was preparing for the musical film Singing in the Rain, her first time as a leading lady, performing alongside the legendary dancer Gene Kelly. She had three dance instructors and practiced spinning for eight hours every day.
六十年後，她在自傳中回憶：「全身上下都在痛，尤其是腦袋和雙腳！」她記得自己癱倒在排練室的鋼琴下，直到另一位傳奇舞者佛雷德．亞斯坦（Fred Astaire）出現，把她哄了起來。「妳不會死的！」他告訴她，「如果妳沒有流汗，表示妳還不夠認真。」於是她從早上八點拍到晚上十一點，然後徹底垮掉，之後好幾天都臥病在床。
Sixty years later, she wrote in her autobiography, "Everything hurt, especially my brain and my feet!" She remembered collapsing under the piano in the rehearsal room until another legendary dancer, Fred Astaire, came and helped her up. "You're not going to die!" he told her. "If you're not sweating, you're not doing it right." So she worked from 8 AM to 11 PM, then completely collapsed and spent the following days in bed.
當時的片廠都有專屬醫師，專門為這些身心俱疲的藝人注射所謂的「維他命針」——實際成分是苯丙胺，也就是俗稱的安非他命。這種做法很可能也毀了茱蒂．嘉蘭（Judy Garland）——這位曾被美國電影學會選為百年最偉大女演員的巨星，最終因藥物過量而意外身亡。
In those days, film studios had their own doctors whose job was to give exhausted performers so-called "vitamin shots." The actual ingredient was amphetamine. This practice likely destroyed Judy Garland, who was once named one of the greatest female movie stars of all time by the American Film Institute. She later died from an accidental drug overdose.
瘦瘦針風潮——好萊塢的減重新寵兒
不切實際的美麗標準
自創立以來，好萊塢一直是個對美貌有著不切實際標準的地方，而這些標準背後往往隱藏著巨大的財務壓力。明星們必須維持纖瘦的身材、充沛的精力，才能獲得更多或更大的成功機會。一旦有人遇到「障礙」——無論是精神萎靡還是情緒低落——掌權者總會想出快速的「解決方案」。
Since its beginning, Hollywood has been a place with unrealistic beauty standards, often connected to enormous financial pressure. Stars must stay thin and energetic to get more opportunities and greater success. Whenever someone faces an "obstacle"—whether mental fatigue or depression—those in power always find quick "solutions."
這些「治療」手段從早期的「維他命針」和興奮劑，演變為苯環利定（PCP）、阿得拉（Adderall，原本用於治療注意力不足過動症的神經興奮劑），甚至是瘦肉精（一種原本用來治療馬匹呼吸問題的藥物）。更別說冷凍溶脂、玻尿酸、肉毒桿菌注射，以及巴西提臀術（自體脂肪移植）等醫美療程——這一切都是為了打造符合社群媒體時代審美標準的完美外表。
These "treatments" evolved from early "vitamin shots" and stimulants to PCP, Adderall (a drug originally used to treat ADHD), and even clenbuterol (a drug originally used to treat breathing problems in horses). There are also cosmetic procedures like CoolSculpting, hyaluronic acid injections, Botox, and the Brazilian Butt Lift (fat transfer surgery)—all designed to create the perfect appearance for the social media age.
每週一針瘦瘦針，體重直直落
（資料來源：nowpatient.com）
近年來，好萊塢又出現了新的減重熱潮。許多人突然在短短幾週內瘦了十到二十公斤，原因並非大家都開始嚴格控制飲食或每天走一萬步，而是一夕之間，人人都在討論一種叫做Semaglutide的注射藥物，品牌名稱是 Ozempic —— 一種胰島素調節劑，後來被暱稱為「瘦瘦針」。
In recent years, a new weight loss trend has emerged in Hollywood. Many people suddenly lost 10 to 20 kilograms in just a few weeks. The reason was not that everyone started controlling their diet or walking 10,000 steps daily. Instead, overnight, everyone began talking about an injectable drug called Semaglutide, sold under the brand name Ozempic—an insulin regulator that later became known as the "skinny shot."
這款藥物由丹麥製藥巨頭諾和諾德（Novo Nordisk）於2012年開發，五年後獲得美國食品藥物管理局（FDA）核准，用於治療第二型糖尿病。其作用原理是刺激胰島素分泌，幫助降低血糖數值，並減緩胃部消化食物的速度。這些「副作用」讓使用者長時間感到飽足，進而自然降低食慾。
This drug was developed by Danish pharmaceutical giant Novo Nordisk in 2012. Five years later, it received approval from the U.S. Food and Drug Administration (FDA) for treating type 2 diabetes. It works by stimulating insulin release, helping to lower blood sugar levels and slowing down how fast the stomach digests food. These "side effects" make users feel full for longer periods, naturally reducing their appetite.
當醫師注意到使用 Ozempic 的病患體重明顯下降時，諾和諾德嗅到了另一個商機。他們針對肥胖及過重族群進行臨床試驗，結果發現這款藥物確實能在數週或數月內，讓體重減輕約百分之十五。很快地，諾和諾德推出了名為 Wegovy 的高劑量版本，專門用於治療肥胖症，每週注射一次，多數人都是買回家自行施打，六到八週就能見效。
When doctors noticed that patients using Ozempic were losing weight, Novo Nordisk saw another business opportunity. They conducted clinical trials on people who were obese or overweight. The results showed that this drug could reduce body weight by about 15 percent within weeks or months. Soon, Novo Nordisk launched a higher-dose version called Wegovy, specifically for treating obesity. It requires one injection per week, and most people give themselves the shots at home. Results can be seen in six to eight weeks.
專家如何看待施打瘦瘦針？
「對於真正需要的人來說，Ozempic 教會人們正確的飲食方式：少量多餐來平衡血糖。血糖愈穩定，壽命就愈長，因為相關疾病也會減少。」這是名人營養治療師金．夏皮拉（Kim Shapira）的看法。她在洛杉磯執業已超過二十年，每週平均接待五十位私人客戶。她發現在新冠疫情期間，美國人平均體重增加了約十三公斤。
"For those who truly need it, Ozempic teaches people what they should be doing: eating smaller meals throughout the day to balance blood sugar. The more stable our blood sugar is, the longer we live, because we develop fewer diseases," says celebrity nutritional therapist Kim Shapira. She has been practicing in Los Angeles for over 20 years and sees about 50 private clients every week. She found that during the COVID-19 pandemic, Americans gained an average of 13 kilograms.
定期施打 Ozempic 確實能減輕體重，降低罹患三高、中風、糖尿病等疾病的風險。由於注射後會降低食慾，也能避免「情緒化進食」。然而，真正的問題不在藥物本身，而在於使用者是否真的需要，以及是否有找專業人士協助解決問題的根源。
Regular Ozempic injections can indeed help people lose weight and reduce the risk of high blood pressure, high cholesterol, stroke, and diabetes. Since the injection reduces appetite, it can also prevent "emotional eating." However, the real issue is not the drug itself, but whether users truly need it and whether they have found professionals to help address the root cause of their problems.
當瘦瘦針成為全民運動
「這感覺就像《綠野仙蹤》的桃樂絲，她的世界突然從黑白變成彩色。一旦你知道 Ozempic 的存在，你的視線範圍內就會到處『出現』它。」一位觀察者如此形容。
"It feels like Dorothy's world in The Wizard of Oz turning from black and white into color. Once you know Ozempic exists, you start 'seeing' it everywhere," one observer described.
這件事看似荒唐卻真實存在。在好萊塢，似乎人人都在尋找 Ozempic。有明星在短時間內成功減重，也不避諱讓他人知道自己有注射。由於方法確實奏效，加上這些人都是螢光幕前的公眾人物，製片人、老闆和朋友們紛紛起而效尤。
This situation seems absurd but is very real. In Hollywood, it seems like everyone is looking for Ozempic. Some celebrities have successfully lost weight in a short time and are not shy about letting others know they use the injection. Because the method actually works, and because these are public figures, producers, bosses, and friends have all followed their example.
接著跟上的是為婚禮做準備的社交名媛、渴望甩掉產後體重的新手媽媽、在校門口竊竊私語的貴婦媽媽們、放棄靠健身器材瘦身的中年商人，以及在健身房路上熱烈討論此事的網紅們。
Following them are socialites preparing for weddings, new mothers wanting to lose their post-pregnancy weight, wealthy mothers whispering at school gates, middle-aged businessmen who have given up on exercise equipment, and social media influencers discussing the topic on their way to the gym.
諷刺的是，有些家長因擔憂疫苗安全性而推遲孩子的預防接種，自己卻早已習慣注射肉毒桿菌，因而對施打 Ozempic 減重這件事莫名感到安心。
Ironically, some parents have delayed their children's vaccinations due to safety concerns, yet they themselves have long been comfortable with Botox injections. This makes them feel strangely reassured about injecting Ozempic for weight loss.
那些對 Ozempic 持開放態度的人，正透過內分泌科、婦產科、心臟科等管道取得這種藥物，據說其中有些醫師對開立處方的標準比較寬鬆。但讓 Ozempic 真正擴散開來的，卻是遠距醫療——有些人為了拿到這張「神奇的瘦身處方」，在視訊看診時甚至謊報體重。
Those who are open to Ozempic are getting prescriptions through endocrinologists, obstetricians, and cardiologists. Some of these doctors reportedly have looser standards for writing prescriptions. But what really spread Ozempic was telemedicine—some people even lie about their weight during video consultations just to get this "miracle weight loss prescription."
科學揭秘——瘦瘦針的原理與常見成分
（資料來源：diabeteswa.com.au）
「瘦瘦針」的主要成分屬於腸泌素類藥物（Incretin-based drugs），如 GLP-1 受體促效劑。其作用機制是模擬體內天然腸泌素的功能，延緩胃排空速度、增加飽足感，進而控制飲食攝取量。這類藥物原本用於第二型糖尿病的血糖控制，後因臨床研究證實對體重管理有幫助，才逐漸應用於肥胖或過重族群的輔助治療。
The main ingredient in "skinny shots" belongs to a class of drugs called incretin-based drugs, such as GLP-1 receptor agonists. These drugs work by mimicking the function of natural incretin hormones in the body. They slow down stomach emptying, increase feelings of fullness, and help control food intake. Originally used for blood sugar control in type 2 diabetes, these drugs are now also used for weight management in people who are obese or overweight.
常見藥物成分包括 Semaglutide（商品名 Wegovy、Ozempic）、Liraglutide（商品名 Saxenda）等，均為美國 FDA 核准、並經台灣衛生福利部核准可用於特定適應症的處方藥物。另有新興藥物 Tirzepatide（商品名 Mounjaro），為同時作用於 GLP-1 與 GIP 受體的雙重腸泌素受體促效劑，目前台灣已核准用於糖尿病控制及體重管理。
Common drug ingredients include Semaglutide (brand names Wegovy and Ozempic) and Liraglutide (brand name Saxenda). These are all FDA-approved prescription drugs, also approved by Taiwan's Ministry of Health and Welfare for specific uses. A newer drug, Tirzepatide (brand name Mounjaro), works on both GLP-1 and GIP receptors. It has been approved in Taiwan for diabetes control and weight management.
瘦瘦針發揮作用的主要機制
抑制食慾、降低飢餓感/Suppressing appetite and reducing hunger
作用於中樞神經的食慾調控區域，減弱對高熱量食物的渴望，幫助控制進食量。
It acts on the appetite control area of the central nervous system, reducing cravings for high-calorie foods and helping control food intake.
延緩胃排空、增加飽足感/Slowing stomach emptying and increasing fullness
影響胰島素與升糖素的分泌，避免餐後血糖快速飆升，促進脂肪更有效地被利用。
It extends the time food stays in the stomach, making the feeling of fullness last longer after meals. This naturally reduces opportunities for extra eating and lowers total calorie intake.
改善胰島素敏感度、穩定血糖/Improving insulin sensitivity and stabilizing blood sugar
影響胰島素與升糖素的分泌，避免餐後血糖快速飆升，促進脂肪更有效地被利用。
It affects the release of insulin and glucagon, preventing blood sugar from rising too quickly after meals. This helps the body use fat more effectively.
根據臨床研究，使用 GLP-1 或 GLP-1／GIP 針劑，搭配飲食與運動調整，約三個月左右即可看見明顯的體重變化；中長期（六至十二個月）變化幅度平均可達體重的百分之十至二十，同時改善血糖、血脂等代謝數值。
According to clinical studies, using GLP-1 or GLP-1/GIP injections together with diet and exercise adjustments can show noticeable weight changes in about three months. Over the medium to long term (six to twelve months), weight loss averages 10 to 20 percent of body weight. Blood sugar and blood fat levels also improve.
使用瘦瘦針前的重要提醒
瘦瘦針屬於處方藥，並非所有人都適合使用。使用前須經合格醫師評估個人病史、體重狀況及潛在風險。療效與副作用因人而異，並非單靠注射即可長期維持理想體重，仍需搭配飲食及生活型態調整，才能達到較佳的體重管理效果。
The skinny shot is a prescription drug, and not everyone is suitable for it. Before use, a qualified doctor must evaluate your medical history, weight condition, and potential risks. Effects and side effects vary from person to person. Injections alone cannot maintain ideal weight in the long term. You must also adjust your diet and lifestyle to achieve better weight management results.
瘦瘦針三大常見成分解析
瘦瘦針的成分由腸泌素類藥物所組成，不同產品的作用時間和機制略有差異。了解這些藥物的特性，有助於選擇適合的治療方式。以下說明三大常見成分：
Skinny shots are made from incretin-based drugs. Different products have slightly different action times and mechanisms. Understanding these characteristics can help people choose the right treatment. Below are the three most common ingredients:
Liraglutide（商品名：Saxenda）
這是一種短效型 GLP-1 受體促效劑，需每日注射一次。它能模擬腸道荷爾蒙 GLP-1 的功能，協助延緩胃排空、增加飽足感，並促進胰島素分泌，有助於飲食控制與血糖穩定。
This is a short-acting GLP-1 receptor agonist that requires one injection per day. It mimics the function of the gut hormone GLP-1, helping to slow down stomach emptying, increase feelings of fullness, and promote insulin release. These effects help with diet control and blood sugar stability.
Semaglutide（商品名：Wegovy、Ozempic）
這是一種長效型 GLP-1 促效劑，每週僅需注射一次。其作用機轉與 Liraglutide 類似，但藥效持續時間更長，可大幅減少注射頻率，同時支持血糖及體重管理。
This is a long-acting GLP-1 agonist that requires only one injection per week. Its mechanism is similar to Liraglutide, but the effects last much longer. This greatly reduces how often injections are needed while supporting blood sugar and weight management.
Tirzepatide（商品名：Mounjaro）
這是新一代的雙重腸泌素受體促效劑，每週注射一次。它同時作用於 GLP-1 與 GIP 兩種受體，用於第二型糖尿病及體重管理的輔助治療，目前已在部分國家核准上市。
This is a new-generation dual incretin receptor agonist that requires one injection per week. It works on both GLP-1 and GIP receptors at the same time. It is used as a supportive treatment for type 2 diabetes and weight management. It has already been approved in some countries.
醫療警訊——數千人提告讓瘦瘦針神話破滅？
（資料來源：rollingstone.com）
根據《今日美國》報導，自 2023 年起，美國已有超過 4,400 名患者對藥廠提出訴訟。這些患者控訴 GLP-1 受體促效劑對他們的身體造成嚴重傷害，並主張藥廠未充分警告可能發生的某些嚴重風險。
According to USA Today, more than 4,400 patients in the United States have filed lawsuits against drug companies since 2023. These patients claim that GLP-1 receptor agonists caused serious harm to their bodies. They also argue that the drug companies did not adequately warn them about certain serious risks.
在這些訴訟案件中，有百分之七十五的原告被診斷出胃麻痺或胃輕癱，另有百分之十八的人出現腸阻塞。此外，約百分之八的原告出現其他嚴重腸胃道併發症，包括嚴重嘔吐、慢性胃食道逆流或腹痛，甚至需要多次住院治療。
In these lawsuits, 75 percent of the plaintiffs were diagnosed with gastroparesis, a condition where the stomach cannot empty properly. Another 18 percent experienced intestinal obstruction. Additionally, about 8 percent of plaintiffs suffered from other serious gastrointestinal complications, including severe vomiting, chronic acid reflux, or abdominal pain. Some even required multiple hospital stays.
除了腸胃問題，部分案例還出現突發性失明、嚴重視力變化、血栓、肺栓塞，以及壞死性胰臟炎等不良反應。不只美國傳出病例，英國藥品和醫療產品監管署也接獲超過千例胰臟炎報告，其中包含十七例死亡個案。
Besides stomach and intestinal problems, some cases also involved sudden blindness, severe vision changes, blood clots, pulmonary embolism, and necrotizing pancreatitis. Reports of problems have come not only from the United States but also from the United Kingdom. The UK Medicines and Healthcare products Regulatory Agency received over 1,000 reports of pancreatitis, including 17 deaths.
兩大藥廠諾和諾德與禮來堅稱，這些藥物已歷經數百項臨床試驗、近二十年的實際使用，並通過美國食品藥物管理局審查，藥品仿單上也有明確標示已知風險。然而，原告認為藥品仿單並未「強調死亡風險」，把有致死副作用的藥物說成「用一輩子也很安全」，讓他們感到受騙。
The two major drug companies, Novo Nordisk and Eli Lilly, insist that these drugs have gone through hundreds of clinical trials, nearly 20 years of actual use, and review by the U.S. Food and Drug Administration. They claim that known risks are clearly stated on the drug labels. However, the plaintiffs believe the labels did not "emphasize the risk of death." They feel deceived because drugs with potentially fatal side effects were described as "safe to use for a lifetime."
台灣專家觀點——使用瘦瘦針前的心理準備與評估
隨著瘦瘦針在台灣快速流行，醫界對其安全性與使用風險的討論逐漸升溫。醫師王姿允提醒，部分民眾與醫療現場對藥物副作用的認知不足，加上風險被淡化，恐成為健康隱憂。
As the skinny shot rapidly gains popularity in Taiwan, discussions about its safety and risks are increasing in the medical community. Dr. Wang Tzu-yun warns that some members of the public and even some medical professionals do not fully understand the drug's side effects. When risks are downplayed, this becomes a health concern.
她指出，不少民眾在接受用藥或手術時，往往抱持著「副作用不會發生在自己身上」的僥倖心態。而部分醫師在說明時，可能過度強調效果、淡化風險，導致民眾低估其嚴重性。
She points out that many people approach medication or surgery with the attitude that "side effects won't happen to me." Some doctors may also overemphasize the benefits while minimizing the risks during their explanations. This causes people to underestimate how serious the side effects can be.
王姿允表示，在美國針對減重針的訴訟中，藥廠的法律責任主要在於研發、臨床研究與揭露已知副作用。至於民眾的用藥心態與醫師的說明方式，並不在藥廠可控制的範圍內。她強調，在判決結果尚未出爐前，仍難以完全釐清相關傷害究竟來自「減重行為本身」還是「藥物直接作用」。
Dr. Wang explains that in the U.S. lawsuits against weight loss injections, the drug companies' legal responsibility mainly involves research, clinical studies, and disclosing known side effects. The attitudes of patients and how doctors explain the drugs are not within the drug companies' control. She emphasizes that until the court decisions are made, it remains difficult to determine whether the harm came from "the weight loss process itself" or "the direct action of the drug."
此外，王姿允也指出，美國案例中出現的胰臟炎、膽結石、嚴重腸胃道副作用及吸入性肺炎，這些症狀往往與「長時間吃不下、喝不下」有關。因此她對會引發噁心、嘔吐、食慾下降的減重藥物持保留態度，認為快速減重本身就伴隨肌肉流失與脫水風險，使用相關藥物必須格外謹慎。她建議以調整飲食進行減重，才不會出現強迫延遲胃排空或因嘔吐導致脫水的問題。
Dr. Wang also notes that in the U.S. cases, symptoms like pancreatitis, gallstones, severe gastrointestinal side effects, and aspiration pneumonia are often related to "being unable to eat or drink for long periods." Therefore, she has reservations about weight loss drugs that cause nausea, vomiting, and loss of appetite. She believes rapid weight loss itself carries risks of muscle loss and dehydration. Using these drugs requires extra caution. She recommends losing weight through diet adjustment to avoid problems like forced delayed stomach emptying or dehydration from vomiting.
她也提醒，美國的訴訟案是自 2023 年累積至今才出現上千名受害者，而台灣對於瘦瘦針仍屬初期流行階段，民眾仍應持續關注可能的副作用。
She also reminds people that the U.S. lawsuits have accumulated thousands of victims since 2023. In Taiwan, the skinny shot trend is still in its early stage. People should continue to pay attention to possible side effects.
除了用藥安全性爭議，停藥後體重反彈的問題也逐漸受到關注。奇美醫院代謝減重中心主治醫師彭瓊慧指出，多數施打瘦瘦針的患者，並未被充分告知「停藥後可能復胖」一事。
Besides safety concerns, the issue of weight rebound after stopping the drug is also receiving attention. Dr. Peng Chiung-hui, an attending physician at Chi Mei Hospital's Metabolic and Weight Management Center, points out that most patients who receive skinny shot injections are not fully informed that they may regain weight after stopping the treatment.
彭瓊慧在門診中經常遇到曾在外院接受瘦瘦針療程的患者，療程結束後體重快速回升，才驚覺問題的嚴重性。她坦言，約有九成患者在施打前並不知道停藥後可能出現明顯反彈，甚至在得知後感到相當震驚。
In her clinic, Dr. Peng often sees patients who received skinny shot treatments at other hospitals. After their treatment ended, their weight quickly returned, and they were shocked to realize how serious the problem was. She admits that about 90 percent of patients did not know before their injections that they might experience significant weight rebound afterward. Many were quite shocked when they learned this fact.
她進一步說明，依臨床觀察，施打後約一年至一年半體重可能降至最低點。若持續施打，體重多半維持穩定；一旦停止使用，體重往往會再度回升，甚至出現明顯反彈。
She further explains that based on clinical observation, weight typically reaches its lowest point about one year to one and a half years after starting injections. If patients continue the injections, their weight usually stays stable. However, once they stop using the drug, their weight often rises again, sometimes with significant rebound.
彭瓊慧也指出，台灣肥胖比例持續攀升，與現代人作息不規律、睡眠不足及長期壓力密切相關。許多體重控制困難的患者，同時伴隨焦慮、憂鬱與睡眠障礙。良好的睡眠有助於分泌「瘦素」，睡不好則可能不利於體重控制。
Dr. Peng also points out that Taiwan's obesity rate continues to rise. This is closely related to modern people's irregular schedules, lack of sleep, and long-term stress. Many patients who have difficulty controlling their weight also suffer from anxiety, depression, and sleep disorders. Good sleep helps the body produce "leptin," a hormone that aids weight control. Poor sleep may make weight management more difficult.
此外，她也觀察到民眾在熬夜或壓力大時，特別容易攝取炸物、泡麵等高熱量食物，生活型態確實會影響體態。她強調，除非患者有明確的醫療需求，如糖尿病或嚴重脂肪肝，否則對於僅以外觀為目標的減重族群，仍會優先建議透過飲食調整、運動與改善作息來達成減重目標。
Additionally, she observes that when people stay up late or experience high stress, they tend to eat high-calorie foods like fried food and instant noodles. Lifestyle truly affects body shape. She emphasizes that unless patients have clear medical needs, such as diabetes or severe fatty liver disease, she will first recommend weight loss through diet adjustment, exercise, and improved sleep habits for those who want to lose weight only for appearance.
瘦瘦針流行的負面影響——令人不適的副作用與市場供不應求
瘦瘦針副作用：噁心、頭痛、極度疲倦
（資料來源：northwell.edu）
許多使用者會出現噁心想吐的症狀，這種不適感可能讓人極度沮喪，甚至癱在床上兩、三天動彈不得。
Many users experience nausea and vomiting. This discomfort can be extremely frustrating and may leave people unable to move for two or three days.
為了抵消這種狀況，不少人不得不服用抗噁心藥物 Zofran。除了噁心之外，有些人還會感到頭痛，對喝酒這件事也變得興趣缺缺。再加上血糖降低的影響，有些人會覺得極度疲累，以至於完全喪失外出用餐的動力。
To counteract this problem, many people have to take anti-nausea medication called Zofran. Besides nausea, some people also experience headaches. Drinking alcohol becomes less enjoyable and appealing. Additionally, because blood sugar levels drop, some people feel extremely tired. They lose all motivation to go out for meals.
瘦瘦針的價格與供應短缺危機
如果你有保險給付，只需支付 25 美元（約新台幣 770元）就能注射一劑 Ozempic。但好萊塢名流們往往選擇自費，每月花費高達 1,500 美元（約新台幣 50,500 元）。
If you have insurance coverage, you only need to pay 25 U.S. dollars (about 770 Taiwan dollars) for one Ozempic injection. However, Hollywood celebrities often choose to pay out of pocket, spending up to 1,500 U.S. dollars (about 50,500 Taiwan dollars) per month.
龐大的需求使得各地藥局供不應求，也讓真正需要 Ozempic 的糖尿病患者難以按時拿到藥物。今年秋天，澳洲醫療用品管理局（TGA）發表聲明指出：「由於消費者需求意外激增……這已嚴重影響第二型糖尿病患者的治療。」該局預計藥品短缺現象將持續數月，並敦促這些患者考慮替代方案。
The huge demand has caused shortages at pharmacies everywhere. This makes it difficult for diabetic patients who truly need Ozempic to get their medication on time. This autumn, Australia's Therapeutic Goods Administration (TGA) issued a statement saying, "Due to an unexpected increase in consumer demand... this has seriously affected the treatment of type 2 diabetes patients." The agency expects the drug shortage to continue for several months. They are urging these patients to consider alternative treatments.
這項決策也已在洛杉磯推行開來。當地藥劑師呼籲持有 Ozempic 處方箋的病患儘早重新配藥，以免延誤病情。
This policy has also been implemented in Los Angeles. Pharmacists there are urging people with Ozempic prescriptions to refill their medication as early as possible to avoid delays in their treatment.
（資料來源：Youtube, What's the science behind weight-loss drugs? - The Food Chain podcast, BBC World Service）
